
LeMaitre Vascular (LMAT) Stock Forecast & Price Target
LeMaitre Vascular (LMAT) Analyst Ratings
Bulls say
LeMaitre Vascular Inc reported significant financial growth, with operating income increasing by 47% year-over-year to $18.8 million and adjusted gross margin improving to 70.4%, indicating strong operational efficiency. The company's organic revenue for full-year 2025 grew by 14%, driven by both price and volume increases, along with a notable regional sales surge in EMEA (+29%) and APAC (+20%). Additionally, strong demand in the Americas, along with emerging opportunities in the Chinese market which experienced 24% growth, further supports a positive outlook for the company's future performance.
Bears say
LeMaitre Vascular Inc. may face significant challenges due to potential technical issues with its mRidium pump, unexpected competition, and regulatory hurdles that could adversely affect financial performance. The company is at risk from lower price increases, competitive pressures, slower international adoption, and potential delays in regulatory approvals, which could negatively impact revenue growth expectations. Additionally, the discrepancy between forecasted and actual revenues, alongside the possibility of reduced reimbursement rates for procedures, further underscores the fundamental risks that could lead to a decline in the company's share value.
This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.
LeMaitre Vascular (LMAT) Analyst Forecast & Price Prediction
Start investing in LeMaitre Vascular (LMAT)
Order type
Buy in
Order amount
Est. shares
0 shares